New Wave of Cancer Immunotherapy Treatments Shows Dramatic Tumor Elimination Results

In February 2024, the FDA approved lifileucel (brand name Amtagvi), the first tumor-infiltrating lymphocyte therapy for a solid cancer — advanced melanoma [1]. The treatment harvests immune cells from a patient's own tumor, expands them in a lab, and reinfuses billions of them to attack the cancer. In real-world use, Amtagvi achieved a 48.8% objective response rate in previously treated melanoma patients, rising to 60.9% when given in earlier lines of therapy [2]. Five-year follow-up data showed a median duration of response of 36.5 months [2].

That approval was one event in a broader acceleration. As of May 2025, 17 bispecific antibodies — engineered proteins that simultaneously bind to immune cells and tumor cells — have received oncology approvals [3]. Next-generation CAR-T cells are producing complete remission rates above 50% in certain blood cancers [4]. And personalized mRNA cancer vaccines, developed by Moderna and Merck, have entered Phase III trials for melanoma [5].

The results are real. But so are the constraints. These therapies cost between $150,000 and $515,000 per patient course, emerge overwhelmingly from small early-phase trials, and require manufacturing infrastructure that most hospitals lack. The gap between clinical trial results and broad patient access remains wide — and the history of oncology drug development suggests that many of these promising treatments will not survive larger trials.

What the Numbers Actually Show

The strongest results for new immunotherapies come from hematologic (blood) cancers. A phase I study of an enhanced CAR-T cell therapy reported a 52% complete remission rate and 81% overall response rate in patients with relapsed or refractory lymphoma [4]. Bispecific antibodies targeting CD20, including mosunetuzumab and glofitamab, have shown high response rates in follicular lymphoma, with one triplet regimen producing a 100% response rate in a small relapsed/refractory cohort [6].

For solid tumors, the picture is more mixed. Lifileucel's 31.4% objective response rate in the registrational melanoma trial, while meaningful for heavily pretreated patients, means roughly two-thirds of patients did not respond [2]. In the only FDA-approved CAR-T indication for a solid tumor — synovial sarcoma — the Phase II SPEARHEAD-1 trial reported a 36% objective response rate and 71% disease control rate in 45 patients [7]. Bispecific antibodies targeting solid tumors have posted lower numbers: an ORR of 28% for a Claudin18.2-targeting agent in gastrointestinal cancers and 19% for a PSMA-targeting agent in castration-resistant prostate cancer [3].

These figures should be compared against established benchmarks. Five-year data for Keytruda (pembrolizumab) plus chemotherapy in metastatic non-small cell lung cancer showed a 19.4% overall survival rate, compared to 11.3% for chemotherapy alone — roughly doubling the odds of being alive at five years [8]. A March 2026 NBER study found that checkpoint inhibitor adoption in melanoma was associated with a 28% reduction in one-year mortality among patients who received the drugs, at a differential cost of $85,000 per patient [9].

The new-wave therapies are generally being tested in patients who have already failed checkpoint inhibitors. Whether they can improve upon — rather than just supplement — existing immunotherapy remains an open question, particularly in solid tumors where the immunosuppressive tumor microenvironment impedes T-cell infiltration and function [7].

Which Patients Benefit — and Which Don't

The biological explanation for the gap between blood cancers and solid tumors is well understood. In hematologic malignancies, tumor cells circulate in the blood and are accessible to engineered immune cells. Solid tumors, by contrast, build physical and biochemical barriers: dense extracellular matrices that block T-cell penetration, metabolic environments that starve immune cells, and checkpoint receptor overexpression that shuts down immune responses [7].

Within solid tumors, melanoma has consistently been the most responsive to immunotherapy, likely because of its high mutational burden — more mutations mean more abnormal proteins (neoantigens) for the immune system to recognize [10]. Cancers with lower mutational burdens, such as pancreatic and prostate cancers, have shown limited responses. TIL therapy trials in non-small cell lung cancer, including PD-L1-negative and low-tumor-mutational-burden patients, are ongoing but have not yet produced registrational data; the Phase II NSCLC trial is expected to complete in late 2026 [11].

Patient subpopulations excluded from or underrepresented in trials include older adults, patients with autoimmune conditions (who risk flares from immune activation), and those with poor performance status. Given that the median age of cancer diagnosis is 66, and many patients have comorbidities that would exclude them from trial enrollment, the real-world applicability of trial results is narrower than headlines suggest [12].

The Toxicity Trade-Off

New immunotherapies carry distinct and sometimes severe side effects. The two signature toxicities are cytokine release syndrome (CRS) — an excessive immune activation that can cause fever, hypotension, and organ damage — and immune effector cell-associated neurotoxicity syndrome (ICANS), which can cause confusion, seizures, and altered consciousness [13].

For bispecific antibodies, CRS of any grade occurs in up to 50% of patients, though severe (grade 3-4) CRS is reported in 1-7% of cases [13]. ICANS occurs in 1-8% of patients [13]. In the epcoritamab trial, grade 1 CRS appeared in 30% of patients, grade 2 in 13%, and grade 3 in 7%, with all cases resolving at a median of 4 days [6]. CAR-T therapies historically carry higher rates: severe CRS has been reported in up to 13% of patients in some trials, and ICANS in up to 28% [13].

For context, standard chemotherapy for advanced cancers produces grade 3-4 adverse events in 40-60% of patients, including neutropenia, anemia, and neuropathy, though the specific toxicity profiles differ substantially [8]. Checkpoint inhibitors carry their own immune-related adverse events — pneumonitis, colitis, hepatitis — affecting roughly 15-20% of patients at grade 3 or higher [12].

Step-up dosing regimens and engineering approaches such as protease-activatable constructs are being developed to reduce CRS and ICANS, but these remain experimental [3].

The Cost Barrier

Source: PMC / GoodRx / NBER

Data as of Jan 1, 2026CSV

The financial scale of new immunotherapies presents a direct access challenge. CAR-T cell therapies carry list prices around $475,000 for a one-time infusion. Amtagvi (lifileucel) is priced at $515,000 per patient [1]. Bispecific antibodies, administered as ongoing infusions rather than one-time treatments, can cost approximately $200,000 per year [14]. A full course of checkpoint inhibitors exceeds $150,000 [9].

The NBER study on checkpoint inhibitors in melanoma found that total treatment costs for Medicare patients who received ICIs were $85,000 higher than for non-recipients — a 263% increase — but this was associated with a 28% reduction in one-year mortality [9]. Whether that cost-benefit ratio holds for therapies priced three to six times higher, in cancers where response rates are lower, is unresolved.

In the United States, Medicare and most private insurers cover FDA-approved immunotherapies, but patient cost-sharing can be substantial [15]. For the approximately 27 million uninsured Americans, these therapies are effectively inaccessible at list prices. In low- and middle-income countries, which bear roughly 70% of global cancer deaths, the Society for Immunotherapy of Cancer (SITC) has noted that clinical trials supporting access are "urgently needed" but remain sparse [16].

Generic competition may eventually ease prices. Key patents for ipilimumab (Yervoy) are expected to expire in 2025-2026 in the US, Japan, and EU, and nivolumab (Opdivo) basic patents expire around 2026 in Europe [5]. But cell therapies like CAR-T and TIL, which involve patient-specific manufacturing rather than mass production, face different economic constraints that patent expiration alone will not resolve.

The Attrition Problem: From Phase II Excitement to Phase III Reality

Source: Nature Reviews Drug Discovery / PMC

Data as of Jan 1, 2025CSV

A central question in evaluating new immunotherapy results is how many of these findings come from early-phase trials with small sample sizes. The answer: most of them. The CAR-T solid tumor data presented at the 2025 ASCO Annual Meeting came from 12 Phase I studies [7]. Bispecific antibody response rates in solid tumors are drawn from Phase I/II dose-escalation cohorts. Even lifileucel's registration was based on a Phase II single-arm trial of 153 patients, receiving accelerated (not full) approval [2].

The historical record for oncology drug development is sobering. Only about 5% of new oncology compounds progress from first-in-human trials to FDA approval, compared to approximately 20% for cardiology drugs [17]. Phase II success rates in oncology hover around 28%, and Phase III success is roughly 42% [17]. In non-small cell lung cancer specifically, 1,631 new agents were studied in Phase II between 1990 and 2005, and only seven received FDA approval [17].

Lack of efficacy accounts for approximately half of all Phase II and Phase III failures, with safety concerns responsible for 22-35% of late-stage failures [17]. The pattern is consistent: small, early-phase trials in selected patient populations often overestimate treatment effects compared to larger, more diverse Phase III populations and real-world settings.

This does not mean the new therapies will fail. But it does mean that extrapolating from Phase I/II data to broad clinical impact involves substantial uncertainty. Tarlatamab, a bispecific T-cell engager for small cell lung cancer, is one of the few in this new wave to have reached Phase III confirmation, gaining full FDA approval based on survival data from the DeLLphi-304 study [3].

Manufacturing and Infrastructure Bottlenecks

Cell therapies face a manufacturing challenge unlike that of conventional drugs. CAR-T production currently requires approximately 50 manual processing steps per dose, totaling more than 80 hours of "touch time" [18]. The process involves collecting a patient's T cells via leukapheresis, shipping them to a centralized facility, genetically modifying them, expanding them, quality-testing them, and shipping them back — all while the patient's cancer continues to progress. Vein-to-vein turnaround times range from three to six weeks.

TIL therapy adds further complexity: tumor tissue must be surgically excised, and the infiltrating lymphocytes must be identified, expanded to billions of cells, and returned to the patient after a lymphodepletion conditioning regimen [11].

Scaling these therapies beyond academic medical centers is a recognized bottleneck. Major centers including Memorial Sloan Kettering, Yale New Haven, and Boston Children's Hospital are already capacity-constrained [18]. Standing up a CAR-T program at a community oncology practice requires a 12-plus-month setup period and seven-figure capital investment for cold storage, apheresis equipment, trained staff, and inpatient monitoring capabilities [19]. Staffing — particularly nurses and pharmacists trained in cell therapy administration and toxicity management — is the primary constraint.

Industry is responding with automation. Closed, automated manufacturing platforms aim to reduce touch time, and collaborations are targeting a 50% reduction in the vein-to-vein cycle [18]. In vivo CAR-T approaches — injecting viral or lipid nanoparticle vectors that reprogram T cells inside the patient's body, eliminating the need for external manufacturing — are in early clinical development [20]. But these solutions are years from commercial availability.

The "Science Fiction" Framing and Patient Expectations

Dr. Lennard Lee of the University of Oxford described personalized mRNA cancer vaccines as "science fiction in real life" — a characterization that captures genuine scientific achievement but also raises concerns about patient expectations [21].

There is measurable evidence that immunotherapy enthusiasm affects clinical decision-making near the end of life. A 2024 study in JAMA Oncology analyzed more than 240,000 patients with metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma treated between 2012 and 2019. The percentage who started immunotherapy within one month of death increased significantly: from 0.8% to 4.3% for melanoma, 0.9% to 3.2% for NSCLC, and 0.5% to 2.6% for kidney cancer [22]. By 2019, more than 1 in 14 immunotherapy treatments were initiated within one month of death [22].

Patients who started immunotherapy that close to death derived minimal benefit. Median survival after late-initiated checkpoint inhibitor treatment was 1.55 months — less time than it typically takes for these drugs to produce a response [23]. Patients with three or more metastatic organ sites were 3.8 times more likely to die within one month of starting immunotherapy than those with lymph node involvement only [22].

STAT News reported in 2017 that oncologists were postponing conversations about palliative care and end-of-life planning because of the hope that immunotherapy would be "the miracle treatment" [23]. The American Society of Clinical Oncology has noted a structural incentive problem: the healthcare system reimburses for systemic therapy but not adequately for hospice benefits, creating financial incentives that favor treatment over palliative care [12].

None of this means immunotherapy should not be offered to appropriate patients. But the framing of "dramatic tumor elimination" and "science fiction" results risks conflating population-level statistical gains — which are real but modest for many cancer types — with individual-level certainty of benefit.

Who Profits: Funding, Patents, and Market Structure

Source: OpenAlex

Data as of Jan 1, 2026CSV

The cancer immunotherapy market was valued at $132.77 billion in 2025 and is projected to grow at 11.6% annually through 2035 [5]. The United States holds approximately 34,000 oncology immunotherapy patents, reflecting both the scale of pharmaceutical investment and the density of intellectual property protection [5].

Pivotal trials are funded through a mix of industry and public sources, though industry dominates later-stage development. The Moderna-Merck personalized mRNA cancer vaccine (intismeran autogene, combined with Keytruda) completed Phase III enrollment with joint corporate funding [5]. Iovance Biotherapeutics funded lifileucel development and holds the commercial rights, though the underlying TIL technology draws on decades of NIH-funded research at the National Cancer Institute — which is currently considering an exclusive patent license for vaccine-augmented TIL technology [24].

Several major patent expirations are approaching. Ipilimumab (Yervoy, Bristol-Myers Squibb) is expected to lose market exclusivity in 2025 in the US and Japan, and in 2026 in the EU. Nivolumab (Opdivo) basic patents expire around 2026 in Europe [5]. These expirations could open the door to biosimilar competition for first-generation checkpoint inhibitors, reducing costs for what are now standard-of-care treatments. But the newer cell therapies and bispecific antibodies are protected by fresh patent portfolios, ensuring years of market exclusivity for their manufacturers.

The financial architecture creates a tension: the treatments most likely to benefit the widest population (checkpoint inhibitors going off-patent) are the cheapest, while the treatments generating the most media excitement (cell therapies, personalized vaccines) are the most expensive and the least proven at scale.

What Comes Next

The immunotherapy field is producing genuine scientific advances. Bispecific antibodies are expanding the range of cancers treatable with immune-directed therapy. TIL therapy has established proof of concept in solid tumors. Personalized mRNA vaccines represent an entirely new therapeutic modality. Research output on cancer immunotherapy grew from roughly 5,100 published papers in 2011 to a peak of more than 80,000 in 2023 [25].

But the path from clinical trial to standard of care is long, expensive, and littered with failures. The 5% overall approval rate for oncology drugs [17], the manufacturing constraints that limit cell therapies to academic medical centers [18], the $500,000-plus price tags that exclude most of the world's cancer patients [1], and the documented tendency for immunotherapy enthusiasm to delay end-of-life planning [22] — all of these factors temper what the clinical data alone might suggest.

For patients today, the practical implications are specific, not sweeping. Patients with relapsed blood cancers have meaningful new options. Melanoma patients who have failed checkpoint inhibitors can now access TIL therapy. For most solid tumor patients, the new wave remains in clinical trials — and the majority of those trials are Phase I or Phase II, with all the uncertainty that entails.

The science is advancing. The question is whether the systems — economic, manufacturing, regulatory, and clinical — can keep pace.